361 related articles for article (PubMed ID: 23624956)
1. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
[TBL] [Abstract][Full Text] [Related]
2. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
Hoxha E; Stahl RA; Harendza S
Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Kronbichler A; Bruchfeld A
Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G;
J Am Soc Nephrol; 2014 Apr; 25(4):850-63. PubMed ID: 24480824
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
[TBL] [Abstract][Full Text] [Related]
14. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
15. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Suzuki Y; Ohara S; Hosoya M
Pediatr Int; 2016 Mar; 58(3):219-223. PubMed ID: 26275234
[TBL] [Abstract][Full Text] [Related]
17. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.
Sinha A; Mathew G; Arushi A; Govindarajan S; Ghanapriya K; Grewal N; Rai K; Brijwal M; Kalluru SL; Tewari P; Misra A; Khandelwal P; Hari P; Bagga A
Nephrol Dial Transplant; 2023 Mar; 38(4):939-949. PubMed ID: 36071552
[TBL] [Abstract][Full Text] [Related]
18. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.
Sato M; Ito S; Ogura M; Kamei K
Pediatr Nephrol; 2014 Aug; 29(8):1373-9. PubMed ID: 24599443
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Gauckler P; Shin JI; Alberici F; Audard V; Bruchfeld A; Busch M; Cheung CK; Crnogorac M; Delbarba E; Eller K; Faguer S; Galesic K; Griffin S; Hrušková Z; Jeyabalan A; Karras A; King C; Kohli HS; Maas R; Mayer G; Moiseev S; Muto M; Odler B; Pepper RJ; Quintana LF; Radhakrishnan J; Ramachandran R; Salama AD; Segelmark M; Tesař V; Wetzels J; Willcocks L; Windpessl M; Zand L; Zonozi R; Kronbichler A;
Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
[TBL] [Abstract][Full Text] [Related]
20. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]